Cellectis (NASDAQ:CLLS) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a report issued on Thursday. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Barclays reduced their price target on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th.

Cellectis Stock Down 2.0 %

Cellectis stock opened at $1.48 on Thursday. Cellectis has a twelve month low of $1.41 and a twelve month high of $3.38. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.78 and a current ratio of 1.78. The firm has a market cap of $82.26 million, a PE ratio of -1.14 and a beta of 3.08. The firm’s 50 day moving average price is $1.83 and its two-hundred day moving average price is $2.00.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The company had revenue of $18.05 million during the quarter, compared to analyst estimates of $5.00 million. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. During the same period last year, the company posted ($0.31) earnings per share. On average, research analysts predict that Cellectis will post -0.46 EPS for the current fiscal year.

Hedge Funds Weigh In On Cellectis

Several institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd bought a new stake in shares of Cellectis during the 2nd quarter worth about $29,000. Long Focus Capital Management LLC lifted its holdings in Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after purchasing an additional 130,000 shares during the last quarter. Finally, First Affirmative Financial Network bought a new stake in Cellectis during the third quarter worth approximately $45,000. 63.90% of the stock is currently owned by institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.